Jishi Pharmaceuticals-B: The long-term survival data of GEMSTONE-302 with Sutuximab re-appears in "The Lancet Oncology".

Jichuang Pharmaceutical-B announced the publication of long-term survival data from a Phase III clinical study of the combination of cetuximab and platinum-based chemotherapy as first-line treatment for stage IV squamous and non-squamous non-small cell lung cancer in the top international medical journal "The Lancet Oncology". Following the publication of the final analysis of progression-free survival and the central analysis of overall survival in "The Lancet Oncology" and "Nature Cancer" respectively, this study once again landed in the same top journal with long-term survival data, completing the evidence chain of cetuximab benefits and further demonstrating its clinical value. This solidifies its position as a standard first-line treatment for advanced NSCLC in China and Europe.